NICE Single Technology Appraisal Guidance No 220 Golimumab for
the treatment of psoriatic arthritis
This NICE Guidance was published today,27 April 2011. The web
reference for the appraisal and other related documents is:
www.nice.org.uk/TA220
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
SMC advice.
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (674/11) on this medication for
this indication in February 2011. This stated that:
Golimumab (Simponi®) is not
recommended for use within NHS Scotland.
Access the advice of the Scottish Medicines Consortium
3. There is a material difference between the
recommendations of the NICE STA and the SMC. NICE recommend
golimumab with restrictions. The NICE STA advice is based upon the
application of a Department of Health agreed Patient Access Scheme.
The manufacturer of golimumab has indicated their intention to
resubmit to the SMC.
If you need further assistance, please contact Eleanor Brownlee in the first
instance tel 0141 225 6873
Published Date: 27 April 2011
